Cannabinoids and omega-3/6 endocannabinoids as cell death and anticancer modulators

Progress in Lipid Research

Volumn 52, Issue 1, 2013, Pages 80-109

  Brown, Iain ^a   Cascio, Maria G ^b   Rotondo, Dino ^c   Pertwee, Roger G ^b   Heys, Steven D ^a   Wahle, Klaus W J ^a,c  

^a UNIVERSITY OF ABERDEEN   (United Kingdom)

^b UNIVERSITY OF ABERDEEN   (United Kingdom)

^c UNIVERSITY OF STRATHCLYDE   (United Kingdom)

Author keywords

2 AG; 2 arachidonoylglycerol; adenosine monophosphate activated protein kinase; AEA; Akt protein kinase B; AMPK; anadamide (arachidonoyl ethanolamide); ANG; angiopoetins; B cell lymphoma 2; BAD; BAX; BCl 2; Bcl 2 associated death promoter; Bcl 2 associated X protein; c Jun N terminal kinase; calcium calmodulin dependent protein kinase kinase 2; CaMKK ; cannabidiol; cannabinoid receptor; CB; CBD; cDNA; CLA; CLnA; complementary DNA; conjugated linoleic acid; conjugated linolenic acid; COX 2; cyclooxygenase 2; DHA; DHEA; DNA binding protein inhibitor 1; docosahexaenoic acid; docosahexaenoyl ethanolamide; eicosapentaenoic acid; eicosapentaenoyl ethanolamide; EPA; EPEA; ERK; extracellular signal regulated kinase; FAAH; fatty acid amide hydrolase; G protein coupled receptor; G protein coupled receptor 55; GPCR; GPR55; HETE; HPETE; hydroperoxyeicosatetraenoic acid; hydroxyeicosatetraenoic acid; ICAM; ID 1; intercellular adhesion molecules; JNK; LCPUFA; lipoxygenase; long chain poly unsaturated fatty acid; LOX; MAGL; mammalian target of rapamycin (mTOR) complex 1; MAPK; matrix metalloproteinases; mitogen activated protein kinase; MMPs; monoacylglycerol lipase; mTORC1; N acylethanolamine; N acylethanolamine acid amidase; N acylphosphatidyl ethanolamine; N acylphosphatidyl ethanolamine hydrolizing phospholipid D; NAAE; NAE; NAPE; NAPE PLD; NF B; nuclear factor kappa light chain enhancer of activated B cells; PAI 1; plasminogen

Indexed keywords

2 ARACHIDONOYLGLYCEROL; ANANDAMIDE; CANNABINOID; CANNABINOID 1 RECEPTOR; CANNABINOID 2 RECEPTOR; CASPASE; CERAMIDE; CYCLIN DEPENDENT KINASE INHIBITOR 1; DOCOSAHEXAENOIC ACID; ENDOCANNABINOID; GROWTH ARREST AND DNA DAMAGE INDUCIBLE PROTEIN 153; ICOSAPENTAENOIC ACID; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; LONG CHAIN FATTY ACID; MITOGEN ACTIVATED PROTEIN KINASE; MITOGEN ACTIVATED PROTEIN KINASE P38; NOLADIN ETHER; OMEGA 3 FATTY ACID; OMEGA 6 FATTY ACID; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR; POLYUNSATURATED FATTY ACID; PROTEIN C JUN; PROTEIN KINASE; PROTEIN P21; PROTEIN P53; PROTEIN P8; TRANSCRIPTION FACTOR; UNINDEXED DRUG; VASCULOTROPIN; VIRODHAMINE; AMIDE; ANTINEOPLASTIC AGENT; ARACHIDONIC ACID DERIVATIVE; CANNABINOID RECEPTOR; CANNABINOID RECEPTOR AGONIST; CANNABINOID RECEPTOR ANTAGONIST;

ANTIINFLAMMATORY ACTIVITY; ANTIPROLIFERATIVE ACTIVITY; APOPTOSIS; AUTOPHAGY; BRAIN TUMOR; CANCER CELL; CANCER INHIBITION; CANCER INVASION; CELL CYCLE ARREST; DRUG MECHANISM; HUMAN; IMMUNOCOMPETENT CELL; IN VITRO STUDY; IN VIVO STUDY; OXIDATIVE STRESS; PRIORITY JOURNAL; REVIEW; ANIMAL; CELL DEATH; CELL PROLIFERATION; DRUG EFFECT; IMMUNOLOGY; METABOLISM; NEOPLASM;

ANIMALIA; MAMMALIA;

ANIMALS; ANTINEOPLASTIC AGENTS; ARACHIDONIC ACIDS; AUTOPHAGY; CANNABINOID RECEPTOR AGONISTS; CANNABINOID RECEPTOR ANTAGONISTS; CANNABINOIDS; CELL DEATH; CELL PROLIFERATION; ENDOCANNABINOIDS; HUMANS; NEOPLASMS; POLYUNSATURATED ALKAMIDES; RECEPTOR, CANNABINOID, CB2; RECEPTORS, CANNABINOID;

MLCS; MLOWN;

EID: 84869869192     PISSN: 01637827     EISSN: 18732194     Source Type: Journal    
DOI: 10.1016/j.plipres.2012.10.001     Document Type: Review

References (343)

1. V. Di Marzo A brief history of cannabinoid and endocannabinoid pharmacology as inspired by the work of British scientists Trends Pharmacol Sci 27 3 2006 134 140
2. R. Mechoulam, and L. Hanus A historical overview of chemical research on cannabinoids Chem Phys Lipids 108 1-2 2000 1 13
3. R.G. Pertwee Cannabinoid pharmacology: the first 66 years Br J Pharmacol 147 Suppl. 1 2006 S163 S171
4. O'Shaughnessy WB. On the preparations of the indian hemp, or gunjah (Cannabis indica). Transact Medic Physic Soc Bengal 1838;1840:421-61.
5. Y. Gaoni, and R. Mechoulam Isolation, structure, and partial synthesis of an active constituent of hashish J Am Chem Soc 86 8 1964 1646 1647
6. M.A. Elsohly, and D. Slade Chemical constituents of marijuana: the complex mixture of natural cannabinoids Life Sci 78 5 2005 539 548
7. A. Alexander, P.F. Smith, and R.J. Rosengren Cannabinoids in the treatment of cancer Cancer Lett 285 1 2009 6 12
8. A.E. Munson, L.S. Harris, M.A. Friedman, W.L. Dewey, and R.A. Carchman Antineoplastic activity of cannabinoids J Natl Cancer Inst 55 3 1975 597 602
9. A.C. White, J.A. Munson, A.E. Munson, and R.A. Carchman Effects of delta9-tetrahydrocannabinol in lewis lung adenocarcinoma cells in tissue culture J Natl Cancer Inst 56 3 1976 655 658
10. R.G. Pertwee, A.C. Howlett, M.E. Abood, S.P. Alexander, V. Di Marzo, and M.R. Elphick International union of basic and clinical pharmacology. LXXIX. cannabinoid receptors and their ligands: beyond CB and CB Pharmacol Rev 62 4 2010 588 631
11. S. Jones, and J. Howl Cannabinoid receptor systems: therapeutic targets for tumour intervention Expert Opin Ther Targets 7 6 2003 749 758
12. R.G. Pertwee Medical uses of cannabinoids: the way forward Addiction 94 3 1999 317 320
13. R. Mechoulam, S. Ben-Shabat, L. Hanus, M. Ligumsky, N.E. Kaminski, and A.R. Schatz Identification of an endogenous 2-monoglyceride, present in canine gut, that binds to cannabinoid receptors Biochem Pharmacol 50 1 1995 83 90
14. Mechoulam R, Spatz M, Shohami E. Endocannabinoids and neuroprotection. Sci STKE 2002;23:(129):re5.
15. H.H. Schmid, and E.V. Berdyshev Cannabinoid receptor-inactive N-acylethanolamines and other fatty acid amides: metabolism and function Prostaglandins Leukot Essent Fatty Acids 66 2-3 2002 363 376
16. R.G. Pertwee, and R.A. Ross Cannabinoid receptors and their ligands Prostaglandins Leukot Essent Fatty Acids 66 2-3 2002 101 121
17. R.G. Pertwee Receptors and channels targeted by synthetic cannabinoid receptor agonists and antagonists Curr Med Chem 17 14 2010 1360 1381
18. S. Burstein, and R. Salmonsen Acylamido analogs of endocannabinoids selectively inhibit cancer cell proliferation Bioorg Med Chem 16 22 2008 9644 9651
19. N. Ueda, K. Tsuboi, and T. Uyama N-Acylethanolamine metabolism with special reference to N-acylethanolamine-hydrolyzing acid amidase (NAAA) Prog Lipid Res 49 4 2010 299 315
20. Calder PC, Dangour AD, Diekman C, Eilander A, Koletzko B, Meijer GW, Mozaffarian D, Niinikoski H, Osendarp SJ, Pietinen P, Schuit J, Uauy R. Essential fats for future health. In: Proceedings of the 9th unilever nutrition symposium. 26-27 May 2010. Eur J Clin Nutr 2010;64 Suppl. 4:S1-13.
21. H. Gleissman, J.I. Johnsen, and P. Kogner Omega-3 fatty acids in cancer, the protectors of good and the killers of evil? Exp Cell Res 316 8 2010 1365 1373
22. Biondo PD, Brindley DN, Sawyer MB, Field CJ. The potential for treatment with dietary long-chain polyunsaturated n-3 fatty acids during chemotherapy. J Nutr Biochem 2008;19(12):787-96.
23. I.M. Berquin, I.J. Edwards, and Y.Q. Chen Multi-targeted therapy of cancer by omega-3 fatty acids Cancer Lett 269 2 2008 363 377
24. K.W.J. Wahle, S.D. Heys, and D. Rotondo Conjugated linoleic acids: are they beneficial or detrimental to health? Prog Lipid Res 43 6 2004 553 587
25. T. Tanaka, M. Hosokawa, Y. Yasui, R. Ishigamori, and K. Miyashita Cancer chemopreventive ability of conjugated linolenic acids Int J Mol Sci 12 2011 7495 7509
26. C.A. Rouzer, and L.J. Marnett Endocannabinoid oxygenation by cyclooxygenases, lipoxygenases and cytochrome P450: cross-talk between eicosanoid and endocannabinoid signaling pathways Chem Rev 111 2011 5899 5921
27. T. Sugiura, S. Kondo, A. Sukagawa, S. Nakame, A. Shinoda, and K. Itoh 2-Arachidonylglycerol: a possible endogenous cannabinoid receptor ligand in brain Biochem Biophys Res Commun 215 1995 89 97
28. T. Bisogno, I. Delton-Vandenbroucke, A. Milone, M. Lagarde, and V. Di Marzo Biosynthesis and inactivation of N-arachidonoylethanolamine (anandamide) and N-docosahexaenoylethanolamine in bovine retina Arch Biochem Biophys 370 1999 300 307
29. Bougnoux P, Hajjaji N, Couet C. The lipidome as a composite biomarker of the modifiable part of the risk of breast cancer. Prostaglandins Leukot Essent Fatty Acids 2008;79(3-5):93-6.
30. B.A. Stoll N-3 fatty acids and lipid peroxidation in breast cancer inhibition Br J Nutr 87 3 2002 193 198
31. M.G. Balvers, K.C. Verhoeckx, P. Plastina, H.M. Wortelboer, J. Meijerink, and R.F. Witkamp Docosahexaenoic acid and eicosapentaenoic acid are converted by 3T3-L1 adipocytes to N-acyl ethanolamines with anti-inflammatory properties Biochim Biophys Acta 1801 10 2010 1107 1114
32. A. Berger, G. Crozier, T. Bisogno, P. Cavaliere, S. Innis, and V. Di Marzo Anandamide and diet: inclusion of dietary arachidonate and docosahexaenoate leads to increased brain levels of the corresponding N-acylethanolamines in piglets Proc Natl Acad Sci U S A 98 11 2001 6402 6406
33. A. Artmann, G. Petersen, L.I. Hellgren, J. Boberg, C. Skonberg, and C. Nellemann Influence of dietary fatty acids on endocannabinoid and N-acylethanolamine levels in rat brain, liver and small intestine Biochim Biophys Acta 1781 4 2008 200 212
34. J. Meijerink, P. Plastina, J.P. Vincken, M. Poland, M. Attya, and M. Balvers The ethanolamide metabolite of DHA, docosahexaenoylethanolamine, shows immunomodulating effects in mouse peritoneal and RAW264.7 macrophages: evidence for a new link between fish oil and inflammation Br J Nutr 4 2011 1 10
35. V. Di Marzo, M. Griinari, G. Carta, E. Murru, A. Ligresti, and L. Cordeddu Dietary krill oil increases docosahexaenoic acid and reduces 2-arachidonoylglycerol but not N-acylethanolamine levels in the brain of obese zucker rats Int Dairy J 20 4 2010 231 235
36. S. Banni, and V. Di Marzo Effect of dietary fat on endocannabinoids and related mediators: consequences on energy homeostasis, inflammation and mood Mol Nutr Food Res 54 1 2010 82 92
37. E. D'Asti, H. Long, J. Tremblay-Mercier, M. Grajzer, S.C. Cunnane, and V. Di Marzo Maternal dietary fat determines metabolic profile and the magnitude of endocannabinoid inhibition of the stress response in neonatal rat offspring Endocrinology 151 4 2010 1685 1694
38. I. Brown, K.W. Wahle, M.G. Cascio, R. Smoum-Jaouni, R. Mechoulam, and R.G. Pertwee Omega-3 N-acylethanolamines are endogenously synthesised from omega-3 fatty acids in different human prostate and breast cancer cell lines Prostaglandins Leukot Essent Fatty Acids 85 6 2011 305 310
39. T. Sheskin, L. Hanus, J. Slager, Z. Vogel, and R. Mechoulam Structural requirements for binding of anandamide-type compounds to the brain cannabinoid receptor J Med Chem 40 5 1997 659 667
40. I.B. Adams, W. Ryan, M. Singer, B.F. Thomas, D.R. Compton, and R.K. Razdan Evaluation of cannabinoid receptor binding and in vivo activities for anandamide analogs J Pharmacol Exp Ther 273 3 1995 1172 1181
41. C.C. Felder, E.M. Briley, J. Axelrod, J.T. Simpson, K. Mackie, and W.A. Devane Anandamide, an endogenous cannabimimetic eicosanoid, binds to the cloned human cannabinoid receptor and stimulates receptor-mediated signal transduction Proc Natl Acad Sci U S A 90 16 1993 7656 7660
42. I. Brown, M.G. Cascio, K.W. Wahle, R. Smoum, R. Mechoulam, and R.A. Ross Cannabinoid receptor-dependent and -independent anti-proliferative effects of omega-3 ethanolamides in androgen receptor-positive and -negative prostate cancer cell lines Carcinogenesis 31 9 2010 1584 1591
43. A.M. Malfitano, E. Ciaglia, G. Gangemi, P. Gazzerro, C. Laezza, and M. Bifulco Update on the endocannabinoid system as an anticancer target Expert Opin Ther Targets 15 3 2011 297 308
44. M. Bifulco, and V. Di Marzo The endocannabinoid system as a target for the development of new drugs for cancer therapy Recenti Prog Med 94 5 2003 194 198
45. S. Pisanti, and M. Bifulco Endocannabinoid system modulation in cancer biology and therapy Pharmacol Res 60 2 2009 107 116
46. V.M. Pushkarev, O.I. Kovzun, and M.D. Tronko Antineoplastic and apoptotic effects of cannabinoids. N-acylethanolamines: protectors or killers? Exp Oncol 30 1 2008 6 21
47. M. Salazar, A. Carracedo, I. Salanuevo, S. Hernandez-Tiedra, M. Lorente, and A. Egia Cannabinoid action induces autophagy-mediated cell death through stimulation of ER stress in human glioma cells J Clin Invest 119 2009 1359 1372
48. D. Vara, M. Salazar, N. Olea-Herrero, M. Guzman, G. Velasco, and I. Diaz-Laviada Antitumoral action of cannabinoids on hepatocellular carcinoma: role of AMPK-dependent activation of autophagy Cell Death Differ 18 2011 1099 1111
49. S.S. Hu, H.B. Bradshaw, J.S. Chen, B. Tan, and J.M. Walker Prostaglandin E2 glycerol ester, an endogenous COX-2 metabolite of 2-arachidonoylglycerol, induces hyperalgesia and modulates NFkappaB activity Br J Pharmacol 153 7 2008 1538 1549
50. M.D. Jhaveri, D. Richardson, I. Robinson, M.J. Garle, A. Patel, and Y. Sun Inhibition of fatty acid amide hydrolase and cyclooxygenase-2 increases levels of endocannabinoid related molecules and produces analgesia via peroxisome proliferator-activated receptor-alpha in a model of inflammatory pain Neuropharmacology 55 1 2008 85 93
51. 2 receptors determines their efficacy at inducing apoptosis in astrocytomas PLoS One 5 1 2010 e8702
52. J.S. Moody, K.R. Kozak, C. Ji, and L.J. Marnett Selective oxygenation of the endocannabinoid 2-arachidonylglycerol by leukocyte-type 12-lipoxygenase Biochemistry 40 4 2001 861 866
53. B.F. Cravatt, and A.H. Lichtman The enzymatic inactivation of the fatty acid amide class of signaling lipids Chem Phys Lipids 121 1-2 2002 135 148
54. B.F. Cravatt, K. Demarest, M.P. Patricelli, M.H. Bracey, D.K. Giang, and B.R. Martin Supersensitivity to anandamide and enhanced endogenous cannabinoid signaling in mice lacking fatty acid amide hydrolase Proc Natl Acad Sci U S A 98 16 2001 9371 9376
55. M. Bifulco, C. Laezza, S. Pisanti, and P. Gazzerro Cannabinoids and cancer: pros and cons of an antitumour strategy Br J Pharmacol 148 2 2006 123 135
56. C.E. Rockwell, P. Raman, B.L. Kaplan, and N.E. Kaminski A COX-2 metabolite of the endogenous cannabinoid, 2-arachidonyl glycerol, mediates suppression of IL-2 secretion in activated jurkat T cells Biochem Pharmacol 76 3 2008 353 361
57. C.J. Fowler, S.B. Gustafsson, S.C. Chung, E. Persson, S.O. Jacobsson, and A. Bergh Targeting the endocannabinoid system for the treatment of cancer-a practical view Curr Top Med Chem 10 8 2010 814 827
58. K.R. Kozak, B.C. Crews, J.L. Ray, H.H. Tai, J.D. Morrow, and L.J. Marnett Metabolism of prostaglandin glycerol esters and prostaglandin ethanolamides in vitro and in vivo J Biol Chem 276 40 2001 36993 36998
59. K.R. Kozak, B.C. Crews, J.D. Morrow, L.H. Wang, Y.H. Ma, and R. Weinander Metabolism of the endocannabinoids, 2-arachidonylglycerol and anandamide, into prostaglandin, thromboxane, and prostacyclin glycerol esters and ethanolamides J Biol Chem 277 47 2002 44877 44885
60. C. Kuc, A. Jenkins, and R.T. Van Dross Arachidonoyl ethanolamide (AEA)-induced apoptosis is mediated by J-series prostaglandins and is enhanced by fatty acid amide hydrolase (FAAH) blockade Mol Carcinog 51 2011 139 149
61. R.A. Ross, S.J. Craib, L.A. Stevenson, R.G. Pertwee, A. Henderson, and J. Toole Pharmacological characterization of the anandamide cyclooxygenase metabolite: prostaglandin E2 ethanolamide J Pharmacol Exp Ther 301 3 2002 900 907
62. S.A. Rieder, A. Chauhan, U. Singh, M. Nagarkatti, and P. Nagarkatti Cannabinoid-induced apoptosis in immune cells as a pathway to immunosuppression Immunobiology 215 8 2010 598 605
63. N. Freimuth, R. Ramer, and B. Hinz Antitumorigenic effects of cannabinoids beyond apoptosis J Pharmacol Exp Ther 332 2 2010 336 344
64. P. Pacher, and R. Mechoulam Is lipid signaling through cannabinoid 2 receptors part of a protective system? Prog Lipid Res 50 2 2011 193 211
65. M.M. Cafferal, C. Andradas, E. Perez-Gomez, M. Guzman, and C. Sanchez Cannabinoids: a hope for breast cancer therapy Cancer Treatment Reviews 38 2012 911 918
66. G. Calvaruso, O. Pellerito, A. Notaro, and M. Guiliano Cannabinoid-associated cell death mechanisms in tumour models (Review) Int J Oncol 41 2012 407 413
67. L.A. Matsuda, S.J. Lolait, M.J. Brownstein, A.C. Young, and T.I. Bonner Structure of a cannabinoid receptor and functional expression of the cloned cDNA Nature 346 6284 1990 561 564
68. A.C. Howlett The cannabinoid receptors Prostaglandins Other Lipid Mediat 68-69 2002 619 631
69. Howlett AC. Cannabinoid receptor signaling. Handb Exp Pharmacol. 2005;(168):53-79.
70. 1 receptor J Neurosci 17 14 1997 5327 5333
71. 1 receptor Eur J Pharmacol 374 3 1999 445 455
72. 1 cannabinoid receptor J Pharmacol Exp Ther 308 3 2004 880 886
73. H.A. Navarro, J.L. Howard, G.T. Pollard, and F.I. Carroll Positive allosteric modulation of the human cannabinoid (CB) receptor by RTI-371, a selective inhibitor of the dopamine transporter Br J Pharmacol 156 7 2009 1178 1184
74. M.M. Caffarel, C. Andradas, E. Mira, E. Perez-Gomez, C. Cerutti, and G. Moreno-Bueno Cannabinoids reduce ErbB2-driven breast cancer progression through akt inhibition Mol Cancer 22 9 2010 196
75. Z. Qamri, A. Preet, M.W. Nasser, C.E. Bass, G. Leone, and S.H. Barsky Synthetic cannabinoid receptor agonists inhibit tumor growth and metastasis of breast cancer Mol Cancer Ther 8 11 2009 3117 3129
76. L. Ruiz, A. Miguel, and I. Diaz-Laviada Delta9-tetrahydrocannabinol induces apoptosis in human prostate PC-3 cells via a receptor-independent mechanism FEBS Lett 458 3 1999 400 404
77. D. Melck, L. De Petrocellis, P. Orlando, T. Bisogno, C. Laezza, and M. Bifulco Suppression of nerve growth factor trk receptors and prolactin receptors by endocannabinoids leads to inhibition of human breast and prostate cancer cell proliferation Endocrinology 141 1 2000 118 126
78. R.J. McKallip, M. Nagarkatti, and P.S. Nagarkatti Delta-9- tetrahydrocannabinol enhances breast cancer growth and metastasis by suppression of the antitumor immune response J Immunol 174 6 2005 3281 3289
79. S. Sarfaraz, F. Afaq, V.M. Adhami, and H. Mukhtar Cannabinoid receptor as a novel target for the treatment of prostate cancer Cancer Res 65 5 2005 1635 1641
80. M.M. Caffarel, D. Sarrio, J. Palacios, M. Guzman, and C. Sanchez Delta9-tetrahydrocannabinol inhibits cell cycle progression in human breast cancer cells through Cdc2 regulation Cancer Res 66 13 2006 6615 6621
81. A. Ligresti, A.S. Moriello, K. Starowicz, I. Matias, S. Pisanti, and L. De Petrocellis Antitumor activity of plant cannabinoids with emphasis on the effect of cannabidiol on human breast carcinoma J Pharmacol Exp Ther 318 3 2006 1375 1387
82. S.C. Chung, P. Hammarsten, A. Josefsson, P. Stattin, T. Granfors, and L. Egevad A high cannabinoid CB(1) receptor immunoreactivity is associated with disease severity and outcome in prostate cancer Eur J Cancer 45 1 2009 174 182
83. G. Czifra, A. Varga, K. Nyeste, R. Marincsak, B.I. Toth, and I. Kovacs Increased expressions of cannabinoid receptor-1 and transient receptor potential vanilloid-1 in human prostate carcinoma J Cancer Res Clin Oncol 135 4 2009 507 514
84. V. Di Marzo, D. Melck, P. Orlando, T. Bisogno, O. Zagoory, and M. Bifulco Palmitoylethanolamide inhibits the expression of fatty acid amide hydrolase and enhances the anti-proliferative effect of anandamide in human breast cancer cells Biochem J 358 Pt. 1 2001 249 255
85. B. Nilius, and T. Voets TRP channels: a TR(I)P through a world of multifunctional cation channels Pflugers Arch 451 1 2005 1 10
86. K. Venkatachalam, and C. Montell TRP channels Annu Rev Biochem 76 2007 387 417
87. V. Di Marzo, L. De Petrocellis, F. Fezza, A. Ligresti, and T. Bisogno Anandamide receptors Prostaglandins Leukot Essent Fatty Acids 66 2-3 2002 377 391
88. P. Holzer Local effector functions of capsaicin-sensitive sensory nerve endings: involvement of tachykinins, calcitonin gene-related peptide and other neuropeptides Neuroscience 24 3 1988 739 768
89. M.J. Caterina, M.A. Schumacher, M. Tominaga, T.A. Rosen, J.D. Levine, and D. Julius The capsaicin receptor: a heat-activated ion channel in the pain pathway Nature 389 6653 1997 816 824
90. M. Tominaga, M.J. Caterina, A.B. Malmberg, T.A. Rosen, H. Gilbert, and K. Skinner The cloned capsaicin receptor integrates multiple pain-producing stimuli Neuron 21 3 1998 531 543
91. R. Marincsak, B.I. Toth, G. Czifra, I. Marton, P. Redl, and I. Tar Increased expression of TRPV1 in squamous cell carcinoma of the human tongue Oral Dis 15 5 2009 328 335
92. N. Qin, M.P. Neeper, Y. Liu, T.L. Hutchinson, M.L. Lubin, and C.M. Flores TRPV2 is activated by cannabidiol and mediates CGRP release in cultured rat dorsal root ganglion neurones J Neurosci 28 2008 6231 6238
93. L. De Petrocellis, A. Ligresti, A.S. Moriello, M Allara, T. Bisogno, and S. Petrosino Effects of cannabinoids and cannabinoid-enriched Cannabis extracts on TRP channels and endocannabinoid metabolic enzymes Br J Pharmacol 163 2011 1479 1494
94. K. Starowicz, S. Nigam, and V. Di Marzo Biochemistry and pharmacology of endovanilloids Pharmacol Ther 114 1 2007 13 33
95. J.-P. Pan, H.-Q. Zhang, W. Wang, Y.-F. Guo, N. Xiao, and X.-H. Cao Some subtypes of endocannabinoid/endovanilloid receptors mediate docosahexaenoic acid-induced enhanced spatial memory in rats Brain Res 1412 2011 18 27
96. J.R. Hibbeln, and J.M. Davis Considerations regarding neuropsychiatric nutritional requirements for omega-3 long chain fatty acid intakes Prostagland Leukot Essent Fatty Acids 81 2009 179 186
97. L. De Petrocellis, K. Starowicz, A. Schiano-Moriello, M. Vivese, P. Orlando, and V. Di Marzo Regulation of transient receptor potential channels of melastatin type 8 (TRPM8): effect of cAMP, cannabinoid CB (1) receptors and endovanilloids Exp Cell Res 313 2007 1911 1920
98. L. De Petrocellis, V. Vellani, A. Schiano-Moriello, P. Marini, P.C. Magherini, and P. Orlando Plant-derived cannabinoids modulate the activity of transient receptor potential channels of ankyrin type-1 and melastatin type-8 J Pharmacol Exp Ther 325 3 2008 1007 1015
99. 2 receptors for endocannabinoids, plant cannabinoids, and synthetic cannabimimetics: focus on G-protein-coupled receptors and transient receptor potential channels J Neuroimmune Pharmacol 5 1 2010 103 121
100. N. Rotman, and W. Wahli PPAR modulation of kinase-linked receptor signaling in physiology and disease Physiology (Bethesda) 25 3 2010 176 185
101. A. Yessoufou, and W. Wahli Multifaceted roles of peroxisome proliferator-activated receptors (PPARs) at the cellular and whole organism levels Swiss Med Wkly 15 140 2010 w13071
102. H. Duez, and B. Staels Nuclear receptors linking circadian rhythms and cardiometabolic control Arterioscler Thromb Vasc Biol 30 8 2010 1529 1534
103. L. Michalik, J. Auwerx, J.P. Berger, V.K. Chatterjee, C.K. Glass, and F.J. Gonzalez International union of pharmacology. LXI. Peroxisome proliferator-activated receptors Pharmacol Rev 58 4 2006 726 741
104. M. Ghosh, H. Wang, Y. Ai, E. Romeo, J.P. Luyendyk, and J.M. Peters COX-2 suppresses tissue factor expression via endocannabinoid-directed PPARdelta activation J Exp Med 204 9 2007 2053 2061
105. N.T. Snider, V.J. Walker, and P.F. Hollenberg Oxidation of the endogenous cannabinoid arachidonoyl ethanolamide by the cytochrome P450 monooxygenases: physiological and pharmacological implications Pharmacol Rev 62 1 2010 136 154
106. K. Gustafsson, X. Wang, D. Severa, M. Eriksson, E. Kimby, and M. Merup Expression of cannabinoid receptors type 1 and type 2 in non-hodgkin lymphoma: growth inhibition by receptor activation Int J Cancer 123 5 2008 1025 1033
107. J. Joseph, B. Niggemann, K.S. Zaenker, and F. Entschladen Anandamide is an endogenous inhibitor for the migration of tumor cells and T lymphocytes Cancer Immunol Immunother 53 8 2004 723 728
108. M. Giuliano, O. Pellerito, P. Portanova, G. Calvaruso, A. Santulli, and A. De Blasio Apoptosis induced in HepG2 cells by the synthetic cannabinoid WIN: involvement of the transcription factor PPARgamma Biochimie 91 4 2009 457 465
109. N. Stella Cannabinoid and cannabinoid-like receptors in microglia, astrocytes, and astrocytomas Glia 58 9 2010 1017 1030
110. A. Carracedo, M. Lorente, A. Egia, C. Blazquez, S. Garcia, and V. Giroux The stress-regulated protein p8 mediates cannabinoid-induced apoptosis of tumor cells Cancer Cell 9 4 2006 301 312
111. M.L. De Jesus, C. Hostalot, J.M. Garibi, J. Salles, J.J. Meana, and L.F. Callado Opposite changes in cannabinoid CB1 and CB2 receptor expression in human gliomas Neurochem Int 56 6-7 2010 829 833
112. U. Pagotto, G. Marsicano, F. Fezza, M. Theodoropoulou, Y. Grubler, and J. Stalla Normal human pituitary gland and pituitary adenomas express cannabinoid receptor type 1 and synthesize endogenous cannabinoids: first evidence for a direct role of cannabinoids on hormone modulation at the human pituitary level J Clin Endocrinol Metab 86 6 2001 2687 2696
113. K. Nithipatikom, M.P. Endsley, M.A. Isbell, J.R. Falck, Y. Iwamoto, and C.J. Hillard 2-Arachidonoylglycerol: a novel inhibitor of androgen-independent prostate cancer cell invasion Cancer Res 64 24 2004 8826 8830
114. F. Cianchi, L. Papucci, N. Schiavone, M. Lulli, L. Magnelli, and M.C. Vinci Cannabinoid receptor activation induces apoptosis through tumor necrosis factor alpha-mediated ceramide de novo synthesis in colon cancer cells Clin Cancer Res 14 23 2008 7691 7700
115. 2 and its ligand 2-arachidonoylglycerol are elevated in endometrial carcinoma Endocrinology 151 3 2010 921 928
116. T. Luca, G. Di Benedetto, M.R. Scuderi, M. Palumbo, S. Clementi, and R. Bernardini The CB1/CB2 receptor agonist WIN-55,212-2 reduces viability of human kaposi's sarcoma cells in vitro Eur J Pharmacol 616 1-3 2009 16 21
117. C. Sanchez, M.L. de Ceballos, T. Gomez del Pulgar, D. Rueda, C. Corbacho, and G. Velasco Inhibition of glioma growth in vivo by selective activation of the CB(2) cannabinoid receptor Cancer Res 61 15 2001 5784 5789
118. 2) expression in adult and pediatric brain tumors Brain Res 1137 1 2007 161 169
119. C.W. Michalski, F.E. Oti, M. Erkan, D. Sauliunaite, F. Bergmann, and P. Pacher Cannabinoids in pancreatic cancer: correlation with survival and pain Int J Cancer 122 4 2008 742 750
120. H. Miyato, J. Kitayama, H. Yamashita, D. Souma, M. Asakage, and J. Yamada Pharmacological synergism between cannabinoids and paclitaxel in gastric cancer cell lines J Surg Res 155 1 2009 40 47
121. 2 correlates with improved prognosis of patients with hepatocellular carcinoma Cancer Genet Cytogenet 171 1 2006 31 38
122. 2R to the G-protein G(alpha)i2beta1gamma2 Neurosci Lett 447 1 2008 68 72
123. I. Galve-Roperh, C. Sanchez, M.L. Cortes, T. Gomez del Pulgar, M. Izquierdo, and M. Guzman Anti-tumoral action of cannabinoids: involvement of sustained ceramide accumulation and extracellular signal-regulated kinase activation Nat Med 6 3 2000 313 319
124. M. Guzman, M.J. Duarte, C. Blazquez, J. Ravina, M.C. Rosa, and I. Galve-Roperh A pilot clinical study of Delta9-tetrahydrocannabinol in patients with recurrent glioblastoma multiforme Br J Cancer 95 2 2006 197 203
125. D. Wang, H. Wang, W. Ning, M.G. Backlund, S.K. Dey, and R.N. DuBois Loss of cannabinoid receptor 1 accelerates intestinal tumor growth Cancer Res 68 15 2008 6468 6476
126. R. Thaler, H. Karlic, P. Rust, and A.G. Haslberger Epigenetic regulation of human buccal mucosa mitochondrial superoxide dismutase gene expression by diet Br J Nutr 7 2008 1 7
127. M. Lazzeri, M.G. Vannucchi, M. Spinelli, E. Bizzoco, P. Beneforti, and D. Turini Transient receptor potential vanilloid type 1 (TRPV1) expression changes from normal urothelium to transitional cell carcinoma of human bladder Eur Urol 48 4 2005 691 698
128. C. Amantini, P. Ballarini, S. Caprodossi, M. Nabissi, M.B. Morelli, and R. Lucciarini Triggering of transient receptor potential vanilloid type 1 (TRPV1) by capsaicin induces Fas/CD95-mediated apoptosis of urothelial cancer cells in an ATM-dependent manner Carcinogenesis 30 8 2009 1320 1329
129. C. Kalogris, S. Caprodossi, C. Amantini, F. Lambertucci, M. Nabissi, and M.B. Morelli Expression of transient receptor potential vanilloid-1 (TRPV1) in urothelial cancers of human bladder: relation to clinicopathological and molecular parameters Histopathology 57 5 2010 744 752
130. C. Amantini, M. Mosca, M. Nabissi, R. Lucciarini, S. Caprodossi, and A. Arcella Capsaicin-induced apoptosis of glioma cells is mediated by TRPV1 vanilloid receptor and requires p38 MAPK activation J Neurochem 102 3 2007 977 990
131. Matta JA, Miyares RL, Ahern GP. TRPV1 is a novel target for omega-3 polyunsaturated fatty acids. J Physiol 2007;578.2:397-411.
132. M. Nabissi, M.B. Morelli, C. Amantini, V. Farfariello, L. Ricci-Vitiani, and S. Caprodossi TRPV2 channel negatively controls glioma cell proliferation and resistance to fas-induced apoptosis in ERK-dependent manner Carcinogenesis 31 5 2010 794 803
133. S. Caprodossi, R. Lucciarini, C. Amantini, M. Nabissi, G. Canesin, and P. Ballarini Transient receptor potential vanilloid type 2 (TRPV2) expression in normal urothelium and in urothelial carcinoma of human bladder: correlation with the pathologic stage Eur Urol 54 3 2008 612 620
134. Yamada T, Ueda T, Shibata Y, Ikegami Y, Saito M, Ishida Y, et al. TRPV2 activation induces apoptotic cell death in human T24 bladder cancer cells: a potential therapeutic target for bladder cancer. Urology 2010;76(2):509.e1,509. e7.
135. V. Lehen'kyi, M. Flourakis, R. Skryma, and N. Prevarskaya TRPV6 channel controls prostate cancer cell proliferation via ca(2+)/NFAT-dependent pathways Oncogene 26 52 2007 7380 7385
136. X.Z. Zhao, H.Q. Guo, G.X. Liu, C.W. Ji, S.W. Zhang, and T.S. Liu Inhibitory effect of TRPV6 silencing on prostate cancer cell line LNCaP in vitro Zhonghua Nan Ke Xue 16 5 2010 423 427
137. C. Van Haute, D. De Ridder, and B. Nilius TRP channels in human prostate Scientific World J 10 2010 1597 1611
138. N. Ueda, R.A. Puffenbarger, S. Yamamoto, and D.G. Deutsch The fatty acid amide hydrolase (FAAH) Chem Phys Lipids 108 1-2 2000 107 121
139. M.K. McKinney, and B.F. Cravatt Structure and function of fatty acid amide hydrolase Annu Rev Biochem 74 2005 411 432
140. G. Labar, and C. Michaux Fatty acid amide hydrolase: from characterization to therapeutics Chem Biodivers 4 8 2007 1882 1902
141. D.J. Hermanson, and L.J. Marnett Cannabinoids, endocannabinoids and cancer Cancer Metastasis Rev 30 2011 599 612
142. D.M. Slipetz, G.P. O'Neill, L. Favreau, C. Dufresne, M. Gallant, and Y. Gareau Activation of the human peripheral cannabinoid receptor results in inhibition of adenylyl cyclase Mol Pharmacol 48 2 1995 352 361
143. Z.H. Song, and T.I. Bonner A lysine residue of the cannabinoid receptor is critical for receptor recognition by several agonists but not WIN55212-2 Mol Pharmacol 49 5 1996 891 896
144. M.R. Johnson, and L.S. Melvin Cannabinoids as Therapeutic Agents R. Mechoulam, 1986 CRC Press Boca Raton 121 145
145. A.C. Howlett, M.R. Johnson, L.S. Melvin, and G.M. Milne Nonclassical cannabinoid analgetics inhibit adenylate cyclase: development of a cannabinoid receptor model Mol Pharmacol 33 3 1988 297 302
146. G. Griffin, P.J. Atkinson, V.M. Showalter, B.R. Martin, and M.E. Abood Evaluation of cannabinoid receptor agonists and antagonists using the guanosine-5′-O-(3-[35S]thio)-triphosphate binding assay in rat cerebellar membranes J Pharmacol Exp Ther 285 2 1998 553 560
147. 2, disrupts G-protein coupling J Pharmacol Exp Ther 285 2 1998 651 658
148. B.R. Martin, D.R. Compton, B.F. Thomas, W.R. Prescott, P.J. Little, and R.K. Razdan Behavioral, biochemical, and molecular modeling evaluations of cannabinoid analogs Pharmacol Biochem Behav 40 3 1991 471 478
149. 2 receptor J Pharmacol Exp Ther 296 2 2001 420 425
150. R.G. Pertwee The therapeutic potential of drugs that target cannabinoid receptors or modulate the tissue levels or actions of endocannabinoids AAPS J 7 3 2005 E625 E654
151. A.T. El-Alfy, K. Ivey, K. Robinson, S. Ahmed, M. Radwan, and D. Slade Antidepressant-like effect of delta9-tetrahydrocannabinol and other cannabinoids isolated from Cannabis sativa L Pharmacol Biochem Behav 95 4 2010 434 442
152. R. Mechoulam, and Y. Gaoni A total synthesis of dl-delta-1- tetrahydrocannabinol, the active constituent of hashish J Am Chem Soc 87 1965 3273 3275
153. R.G. Pertwee Ligands that target cannabinoid receptors in the brain: from THC to anandamide and beyond Addict Biol 13 2 2008 147 159
154. C.E. Chang, R. Ai, M. Gutierrez, and M.J. Marsella Homology modeling of cannabinoid receptors: discovery of cannabinoid analogues for therapeutic use Methods Mol Biol 819 2012 595 613
155. R. Mechoulam, Y. Shvo, and I. Hashish The structure of cannabidiol Tetrahedron 19 12 1963 2073 2078
156. 2 receptor pharmacology of three plant cannabinoids: delta9-tetrahydrocannabinol, cannabidiol and delta9-tetrahydrocannabivarin Br J Pharmacol 153 2 2008 199 215
157. Jacob A, Todd A. Cannabis indica. Part II. Isolation of cannabidiol from Egyptian hashish. observations on the structure of cannabinol. J Chem Soc 1940:649-53.
158. R. Adams Marihuana Science 92 2380 1940 115 119
159. Y. Gaoni, R. Mechoulam, and Hashish Isomerization of cannabidiol to tetrahydrocannabinols Tetrahedron 22 1966 1481
160. U. Claussen, and F. Korte Phenolic compounds of the hemp plant and their conversion to hasish compounds Justus Liebigs Ann Chem 713 1968 166 174
161. E.W. Gill, W.D. Paton, and R.G. Pertwee Preliminary experiments on the chemistry and pharmacology of cannabis Nature 228 5267 1970 134 136
162. W.A. Devane, L. Hanus, A. Breuer, R.G. Pertwee, L.A. Stevenson, and G. Griffin Isolation and structure of a brain constituent that binds to the cannabinoid receptor Science 258 5090 1992 1946 1949
163. L.O. Hanus Discovery and isolation of anandamide and other endocannabinoids Chem Biodivers 4 8 2007 1828 1841
164. V. Di Marzo, T. Bisogno, and L. De Petrocellis Anandamide: some like it hot Trends Pharmacol Sci 22 7 2001 346 349
165. A. Al-Hayani, K.N. Wease, R.A. Ross, R.G. Pertwee, and S.N. Davies The endogenous cannabinoid anandamide activates vanilloid receptors in the rat hippocampal slice Neuropharmacology 41 8 2001 1000 1005
166. D. Smart, M.J. Gunthorpe, J.C. Jerman, S. Nasir, J. Gray, and A.I. Muir The endogenous lipid anandamide is a full agonist at the human vanilloid receptor (hVR1) Br J Pharmacol 129 2 2000 227 230
167. T. Sugiura, S. Kondo, A. Sukagawa, S. Nakane, A. Shinoda, and K. Itoh 2-Arachidonoylglycerol: a possible endogenous cannabinoid receptor ligand in brain Biochem Biophys Res Commun 215 1 1995 89 97
168. 1 receptor J Pharmacol Exp Ther 301 3 2002 1020 1024
169. H.B. Bradshaw, and J.M. Walker The expanding field of cannabimimetic and related lipid mediators Br J Pharmacol 144 4 2005 459 465
170. 1 receptor Proc Natl Acad Sci U S A 98 7 2001 3662 3665
171. B. Majumder, K.W. Wahle, S. Moir, A. Schofield, S.N. Choe, and A. Farquharson Conjugated linoleic acids (CLAs) regulate the expression of key apoptotic genes in human breast cancer cells FASEB J 16 11 2002 1447 1449
172. Fite A, Goua M, Wahle KJ, Schofield A, Hutcheon A, Heys S. Potentiation of the anti-tumour effect of docetaxel by conjugated linoleic acids (CLAs) in breast cancer cells in vitro. Prostaglandins Leukot Essent Fatty Acids 2007 8;77(2):87-96.
173. P.C. Schmid, P.V. Reddy, V. Natarajan, and H.H. Schmid Metabolism of N-acylethanolamine phospholipids by a mammalian phosphodiesterase of the phospholipase D type J Biol Chem. 258 15 1983 9302 9306
174. H.H. Schmid, P.C. Schmid, and V. Natarajan N-Acylated glycerophospholipids and their derivatives Prog Lipid Res 29 1 1990 1 43
175. H.S. Hansen, L. Lauritzen, B. Moesgaard, A.M. Strand, and H.H. Hansen Formation of N-acyl-phosphatidylethanolamines and N-acetylethanolamines: proposed role in neurotoxicity Biochem Pharmacol 55 6 1998 719 725
176. V. Di Marzo, A. Fontana, H. Cadas, S. Schinelli, G. Cimino, and J.C. Schwartz Formation and inactivation of endogenous cannabinoid anandamide in central neurons Nature 372 6507 1994 686 691
177. H.S. Hansen, B. Moesgaard, H.H. Hansen, and G. Petersen N-Acylethanolamines and precursor phospholipids-relation to cell injury Chem Phys Lipids 108 1-2 2000 135 150
178. P.C. Schmid, K.D. Schwartz, C.N. Smith, R.J. Krebsbach, E.V. Berdyshev, and H.H. Schmid A sensitive endocannabinoid assay. The simultaneous analysis of N-acylethanolamines and 2-monoacylglycerols Chem Phys Lipids 104 2 2000 185 191
179. L. Aravind An evolutionary classification of the metallo-beta-lactamase fold proteins In Silico Biol 1 2 1999 69 91
180. H. Daiyasu, K. Osaka, Y. Ishino, and H. Toh Expansion of the zinc metallo-hydrolase family of the beta-lactamase fold FEBS Lett 503 1 2001 1 6
181. Q. Liu, T. Tonai, and N. Ueda Activation of N-acylethanolamine-releasing phospholipase D by polyamines Chem Phys Lipids 115 1-2 2002 77 84
182. Y. Okamoto, J. Morishita, K. Tsuboi, T. Tonai, and N. Ueda Molecular characterization of a phospholipase D generating anandamide and its congeners J Biol Chem 279 7 2004 5298 5305
183. G. Petersen, K.D. Chapman, and H.S. Hansen A rapid phospholipase D assay using zirconium precipitation of anionic substrate phospholipids: application to n-acylethanolamine formation in vitro J Lipid Res 41 9 2000 1532 1538
184. J. Wang, L.Y. Zhao, T. Uyama, K. Tsuboi, X.X. Wu, and Y. Kakehi Expression and secretion of N-acylethanolamine-hydrolysing acid amidase in human prostate cancer cells J Biochem 144 5 2008 685 690
185. Y.X. Sun, K. Tsuboi, Y. Okamoto, T. Tonai, M. Murakami, and I. Kudo Biosynthesis of anandamide and N-palmitoylethanolamine by sequential actions of phospholipase A2 and lysophospholipase D Biochem J 380 Pt. 3 2004 749 756
186. G.M. Simon, and B.F. Cravatt Endocannabinoid biosynthesis proceeding through glycerophospho-N-acyl ethanolamine and a role for alpha/beta-hydrolase 4 in this pathway J Biol Chem 281 36 2006 26465 26472
187. L. Renault, V. Negre, T. Hotelier, X. Cousin, P. Marchot, and A. Chatonnet New friendly tools for users of ESTHER, the database of the alpha/beta-hydrolase fold superfamily of proteins Chem Biol Interact 157-158 2005 339 343
188. J. Liu, L. Wang, J. Harvey-White, D. Osei-Hyiaman, R. Razdan, and Q. Gong A biosynthetic pathway for anandamide Proc Natl Acad Sci U S A 103 36 2006 13345 13350
189. D.G. Deutsch, and S.A. Chin Enzymatic synthesis and degradation of anandamide, a cannabinoid receptor agonist Biochem Pharmacol 46 5 1993 791 796
190. Kruszka KK, Gross RW. The ATP- and CoA-independent synthesis of arachidonoylethanolamide. A novel mechanism underlying the synthesis of the endogenous ligand of the cannabinoid receptor. J Biol Chem 1994;269(20):14345-8.
191. W.A. Devane, and J. Axelrod Enzymatic synthesis of anandamide, an endogenous ligand for the cannabinoid receptor, by brain membranes Proc Natl Acad Sci U S A 91 14 1994 6698 6701
192. N. Ueda Anandamide: an endogenous cannabinoid receptor agonist Seikagaku 67 8 1995 1036 1040
193. K. Katayama, N. Ueda, I. Katoh, and S. Yamamoto Equilibrium in the hydrolysis and synthesis of cannabimimetic anandamide demonstrated by a purified enzyme Biochim Biophys Acta 1440 2-3 1999 205 214
194. M.M. Joosten, M.G. Balvers, K.C. Verhoeckx, H.F. Hendriks, and R.F. Witkamp Plasma anandamide and other N-acylethanolamines are correlated with their corresponding free fatty acid levels under both fasting and non-fasting conditions in women Nutr Metab (Lond) 14 7 2010 49
195. B. Batetta, M. Griinari, G. Carta, E. Murru, A. Ligresti, and L. Cordeddu Endocannabinoids may mediate the ability of (n-3) fatty acids to reduce ectopic fat and inflammatory mediators in obese zucker rats J Nutr 139 8 2009 1495 1501
196. M. Lafourcade, T. Larrieu, S. Mato, A. Duffaud, M. Sepers, and I. Matias Nutritional omega-3 deficiency abolishes endocannabinoid-mediated neuronal functions Nat Neurosci 14 3 2011 345 350
197. N. Ueda, K. Tsuboi, and T. Uyama Enzymological studies on the biosynthesis of N-acylethanolamines Biochim Biophys Acta 1801 12 2010 1274 1285
198. T. Moriyama, R. Urade, and M. Kito Purification and characterization of diacylglycerol lipase from human platelets J Biochem 125 6 1999 1077 1085
199. T. Bisogno, F. Howell, G. Williams, A. Minassi, M.G. Cascio, and A. Ligresti Cloning of the first sn1-DAG lipases points to the spatial and temporal regulation of endocannabinoid signaling in the brain J Cell Biol 163 3 2003 463 468
200. E.J. Williams, F.S. Walsh, and P. Doherty The FGF receptor uses the endocannabinoid signaling system to couple to an axonal growth response J Cell Biol 160 4 2003 481 486
201. Y. Gao, D.V. Vasilyev, M.B. Goncalves, F.V. Howell, C. Hobbs, and M. Reisenberg Loss of retrograde endocannabinoid signaling and reduced adult neurogenesis in diacylglycerol lipase knock-out mice J Neurosci 30 6 2010 2017 2024
202. B.F. Cravatt, D.K. Giang, S.P. Mayfield, D.L. Boger, R.A. Lerner, and N.B. Gilula Molecular characterization of an enzyme that degrades neuromodulatory fatty-acid amides Nature 384 6604 1996 83 87
203. F. Desarnaud, H. Cadas, and D. Piomelli Anandamide amidohydrolase activity in rat brain microsomes. identification and partial characterization J Biol Chem 270 11 1995 6030 6035
204. K. Katayama, N. Ueda, Y. Kurahashi, H. Suzuki, S. Yamamoto, and I. Kato Distribution of anandamide amidohydrolase in rat tissues with special reference to small intestine Biochim Biophys Acta 1347 2-3 1997 212 218
205. Y.X. Sun, K. Tsuboi, L.Y. Zhao, Y. Okamoto, D.M. Lambert, and N. Ueda Involvement of N-acylethanolamine-hydrolyzing acid amidase in the degradation of anandamide and other N-acylethanolamines in macrophages Biochim Biophys Acta 1736 3 2005 211 220
206. S.J. Reilly, E.M. O'Shea, U. Andersson, J. O'Byrne, S.E. Alexson, and M.C. Hunt A peroxisomal acyltransferase in mouse identifies a novel pathway for taurine conjugation of fatty acids FASEB J 21 1 2007 99 107
207. D.K. Giang, and B.F. Cravatt Molecular characterization of human and mouse fatty acid amide hydrolases Proc Natl Acad Sci U S A 94 6 1997 2238 2242
208. B.Q. Wei, T.S. Mikkelsen, M.K. McKinney, E.S. Lander, and B.F. Cravatt A second fatty acid amide hydrolase with variable distribution among placental mammals J Biol Chem 281 48 2006 36569 36578
209. S. Maurelli, T. Bisogno, L. De Petrocellis, A. Di Luccia, G. Marino, and V. Di Marzo Two novel classes of neuroactive fatty acid amides are substrates for mouse neuroblastoma 'anandamide amidohydrolase' FEBS Lett 377 1 1995 82 86
210. A. Saghatelian, S.A. Trauger, E.J. Want, E.G. Hawkins, G. Siuzdak, and B.F. Cravatt Assignment of endogenous substrates to enzymes by global metabolite profiling Biochemistry 43 45 2004 14332 14339
211. N. Ueda, K. Katayama, Y. Kurahashi, M. Suzuki, H. Suzuki, and S. Yamamoto Enzymological and molecular biological studies on anandamide amidohydrolase Adv Exp Med Biol 469 1999 513 518
212. K. Tsuboi, N. Takezaki, and N. Ueda The N-acetylethanolamine-hydrolysing acid amidase (NAAA) Chem Biodiversity 4 2007 1914 1925
213. K. Ferlinz, G. Kopal, K. Bernardo, T. Linke, J. Bar, and B. Breiden Human acid ceramidase: processing, glycosylation, and lysosomal targeting J Biol Chem 276 38 2001 35352 35360
214. H. Schulze, U. Schepers, and K. Sandhoff Overexpression and mass spectrometry analysis of mature human acid ceramidase Biol Chem 388 12 2007 1333 1343
215. N. Ueda, K. Yamanaka, K. Katayama, S.K. Goparaju, H. Suzuki, and S. Yamamoto Alkaline and acid amidases hydrolyzing anandamide and other N-acylethanolamines World Rev Nutr Diet 88 2001 215 222
216. K. Tsuboi, Y.X. Sun, Y. Okamoto, N. Araki, T. Tonai, and N. Ueda Molecular characterization of N-acylethanolamine-hydrolyzing acid amidase, a novel member of the choloylglycine hydrolase family with structural and functional similarity to acid ceramidase J Biol Chem 280 12 2005 11082 11092
217. J.L. Blankman, G.M. Simon, and B.F. Cravatt A comprehensive profile of brain enzymes that hydrolyze the endocannabinoid 2-arachidonoylglycerol Chem Biol 14 12 2007 1347 1356
218. S.K. Goparaju, N. Ueda, K. Taniguchi, and S. Yamamoto Enzymes of porcine brain hydrolyzing 2-arachidonoylglycerol, an endogenous ligand of cannabinoid receptors Biochem Pharmacol 57 4 1999 417 423
219. B. Hinz, R. Ramer, K. Eichele, U. Weinzierl, and K. Brune Up-regulation of cyclooxygenase-2 expression is involved in R(+)-methanandamide-induced apoptotic death of human neuroglioma cells Mol Pharmacol 66 6 2004 1643 1651
220. R.J. Flower New directions in cyclooxygenase research and their implications for NSAID-gastropathy Ital J Gastroenterol 28 Suppl. 4 1996 23 27
221. C.J. Fowler The contribution of cyclooxygenase-2 to endocannabinoid metabolism and action Br J Pharmacol 152 5 2007 594 601
222. M.L. Yates, and E.L. Barker Inactivation and biotransformation of the endogenous cannabinoids anandamide and 2-arachidonoylglycerol Mol Pharmacol 76 1 2009 11 17
223. R.T. Van Dross Metabolism of anandamide by COX-2 is necessary for endocannabinoid-induced cell death in tumorigenic keratinocytes Mol Carcinog 48 8 2009 724 732
224. J. Guindon, and A.G. Hohmann A physiological role for endocannabinoid-derived products of cyclooxygenase-2-mediated oxidative metabolism Br J Pharmacol 153 7 2008 1341 1343
225. M. Van der Stelt, J.A. van Kuik, M. Bari, G. van Zadelhoff, B.R. Leeflang, and G.A. Veldink Oxygenated metabolites of anandamide and 2-arachidonoylglycerol: conformational analysis and interaction with cannabinoid receptors, membrane transporter, and fatty acid amide hydrolase J Med Chem 45 17 2002 3709 3720
226. N. Sang, J. Zhang, and C. Chen COX-2 oxidative metabolite of endocannabinoid 2-AG enhances excitatory glutamatergic synaptic transmission and induces neurotoxicity J Neurochem 102 6 2007 1966 1977
227. M. Yu, D. Ives, and C.S. Ramesha Synthesis of prostaglandin E2 ethanolamide from anandamide by cyclooxygenase-2 J Biol Chem 272 34 1997 21181 21186
228. K.R. Kozak, S.W. Rowlinson, and L.J. Marnett Oxygenation of the endocannabinoid, 2-arachidonylglycerol, to glyceryl prostaglandins by cyclooxygenase-2 J Biol Chem 275 43 2000 33744 33749
229. R.A. Ross, A.A. Coutts, S.M. McFarlane, S. Anavi-Goffer, A.J. Irving, and R.G. Pertwee Actions of cannabinoid receptor ligands on rat cultured sensory neurones: implications for antinociception Neuropharmacology 40 2 2001 221 232
230. L. De Petrocellis, D. Melck, T. Bisogno, and V. Di Marzo Endocannabinoids and fatty acid amides in cancer, inflammation and related disorders Chem Phys Lipids 108 1-2 2000 191 209
231. G. Furstenberger, P. Krieg, K. Muller-Decker, and A.J. Habenicht What are cyclooxygenases and lipoxygenases doing in the driver's seat of carcinogenesis? Int J Cancer 119 10 2006 2247 2254
232. D.P. Rose, and J.M. Connolly Effects of dietary omega-3 fatty acids on human breast cancer growth and metastasis in nude mice J Natl Cancer Inst 85 1993 1743 1747
233. N. Ueda, K. Yamamoto, S. Yamamoto, T. Tokunaga, E. Shirakawa, and H. Shinkai Lipoxygenase-catalyzed oxygenation of arachidonylethanolamide, a cannabinoid receptor agonist Biochim Biophys Acta 1254 2 1995 127 134
234. A.J. Hampson, W.A. Hill, M. Zan-Phillips, A. Makriyannis, E. Leung, and R.M. Eglen Anandamide hydroxylation by brain lipoxygenase:metabolite structures and potencies at the cannabinoid receptor Biochim Biophys Acta 1259 2 1995 173 179
235. P. Massi, M. Valenti, A. Vaccani, V. Gasperi, G. Perletti, and E. Marras 5-lipoxygenase and anandamide hydrolase (FAAH) mediate the antitumor activity of cannabidiol, a non-psychoactive cannabinoid J Neurochem 104 4 2008 1091 1100
236. C.N. Serhan, S. Krishnamoorthy, A. Recchiuti, and N. Chiang Novel anti-inflammatory-pro-resolving mediators and their receptors Curr Top Med Chem 11 6 2011 629 647
237. B.D. Levy Resolvins and protectins: natural pharmacophores for resolution biology Prostaglandins Leukot Essent Fatty Acids 82 4-6 2010 327 332
238. K. Stark, M. Dostalek, and F.P. Guengerich Expression and purification of orphan cytochrome P450 4X1 and oxidation of anandamide FEBS J 275 2008 3706 3717
239. J. Chen, J.K. Chen, J.R. Falck, J.S. Guthi, S. Anjaiah, and J.H. Capdevila Mitogenic activity and signaling mechanism of 2-(14,15- epoxyeicosatrienoyl)glycerol, a novel cytochrome P450 arachidonate metabolite Mol Cell Biol 27 8 2007 3023 3034
240. M. Salazar, A. Carracedo, I.J. Salanuevo, S. Hernandez-Tiedra, and A. Egia TRB3 links ER stress to autophagy in cannabinoid anti-tumoral action Autophagy 5 1999 1048 1049
241. A. Shrivastava, P.M. Kuzontkoski, J.E. Groopman, and A. Prasad Cannabidiol induces programmed cell death in breast cancer cells by coordinating the cross-talk between apoptosis and autophagy Mol Cancer Ther 10 2011 1161 1172
242. P. Massi, A. Vaccani, S. Bianchessi, B. Costa, P. Macchi, and D. Parolaro The non-psychoactive cannabidiol triggers caspase activation and oxidative stress in human glioma cells Cell Mol Life Sci 63 2006 2057 2066
243. L.L. Pearson, B.E. Castle, and M.R. Kehry CD40-mediated signaling in monocytic cells: up-regulation of tumor necrosis factor receptor-associated factor mRNAs and activation of mitogen-activated protein kinase signaling pathways Int Immunol 13 3 2001 273 283
244. S. Sarfaraz, F. Afaq, V.M. Adhami, A. Malik, and H. Mukhtar Cannabinoid receptor agonist-induced apoptosis of human prostate cancer cells LNCaP proceeds through sustained activation of ERK1/2 leading to G1 cell cycle arrest J Biol Chem 281 51 2006 39480 39491
245. W. Jia, V.L. Hegde, N.P. Singh, D. Sisco, S. Grant, and M. Nagarkatti Delta9-tetrahydrocannabinol-induced apoptosis in jurkat leukemia T cells is regulated by translocation of bad to mitochondria Mol Cancer Res 4 8 2006 549 562
246. 2 receptor-induced apoptosis of human leukaemia cells FEBS Lett 579 22 2005 5084 5088
247. S.G. Kennedy, A.J. Wagner, S.D. Conzen, J. Jordan, A. Bellacosa, and P.N. Tsichlis The PI 3-kinase/Akt signaling pathway delivers an anti-apoptotic signal Genes Dev 11 6 1997 701 713
248. B. Rayet, and C. Gelinas Aberrant rel/nfkb genes and activity in human cancer Oncogene 18 49 1999 6938 6947
249. A.B. El-Remessy, Y. Tang, G. Zhu, S. Matragoon, Y. Khalifa, and E.K. Liu Neuroprotective effects of cannabidiol in endotoxin-induced uveitis: critical role of p38 MAPK activation Mol Vis 14 2008 2190 2203
250. A. Ozaita, E. Puighermanal, and R. Maldonado Regulation of PI3K/Akt/GSK-3 pathway by cannabinoids in the brain J Neurochem 102 4 2007 1105 1114
251. A. Ellert-Miklaszewska, B. Kaminska, and L. Konarska Cannabinoids down-regulate PI3K/Akt and erk signalling pathways and activate proapoptotic function of bad protein Cell Signal 17 1 2005 25 37
252. I. Galve-Roperh, D. Rueda, T. Gomez del Pulgar, G. Velasco, and M. Guzman Mechanism of extracellular signal-regulated kinase activation by the CB(1) cannabinoid receptor Mol Pharmacol 62 6 2002 1385 1392
253. Gomez del Pulgar T, Velasco G, Guzman M, The CB1 cannabinoid receptor is coupled to the activation of protein kinase B/Akt, Biochem J 2000;347(Pt. 2):369-73.
254. E.J. Downer, A. Gowran, A.C. Murphy, and V.A. Campbell The tumour suppressor protein, p53, is involved in the activation of the apoptotic cascade by Delta9-tetrahydrocannabinol in cultured cortical neurons Eur J Pharmacol 564 1-3 2007 57 65
255. N. Pasquariello, G. Catanzaro, V. Marzano, D. Amadio, D. Barcaroli, and S. Oddi Characterization of the endocannabinoid system in human neuronal cells and proteomic analysis of anandamide-induced apoptosis J Biol Chem 284 43 2009 29413 29426
256. T. Powles, R. te Poele, J. Shamash, T. Chaplin, D. Propper, and S. Joel Cannabis-induced cytotoxicity in leukemic cell lines: the role of the cannabinoid receptors and the MAPK pathway Blood 105 3 2005 1214 1221
257. K. Woodson, J. Mason, S.W. Choi, T. Hartman, J. Tangrea, and J. Virtamo Hypomethylation of p53 in peripheral blood DNA is associated with the development of lung cancer Cancer Epidemiol Biomarkers Prev 10 1 2001 69 74
258. A.R. Karpf, B.C. Moore, T.O. Ririe, and D.A. Jones Activation of the p53 DNA damage response pathway after inhibition of DNA methyltransferase by 5-aza-2′-deoxycytidine Mol Pharmacol 59 4 2001 751 757
259. J.L. Perfettini, M. Castedo, R. Nardacci, F. Ciccosanti, P. Boya, and T. Roumier Essential role of p53 phosphorylation by p38 MAPK in apoptosis induction by the HIV-1 envelope J Exp Med 201 2 2005 279 289
260. G. Velasco, I. Galve-Roperh, C. Sanchez, C. Blazquez, A. Haro, and M. Guzman Cannabinoids and ceramide: two lipids acting hand-by-hand Life Sci 77 14 2005 1723 1731
261. M. Guzman, C. Sanchez, and I. Galve-Roperh Control of the cell survival/death decision by cannabinoids J Mol Med 78 11 2001 613 625
262. C. Laezza, S. Pisanti, E. Crescenzi, and M. Bifulco Anandamide inhibits Cdk2 and activates Chk1 leading to cell cycle arrest in human breast cancer cells FEBS Lett 580 26 2006 6076 6082
263. I.A. Shaikh, I. Brown, A.C. Schofield, K.W. Wahle, and S.D. Heys Docosahexaenoic acid enhances the efficacy of docetaxel in prostate cancer cells by modulation of apoptosis: the role of genes associated with the NF-kappaB pathway Prostate 68 15 2008 1635 1646
264. K. Eichele, R. Ramer, and B. Hinz R(+)-Methanandamide-induced apoptosis of human cervical carcinoma cells involves a cyclooxygenase-2-dependent pathway Pharm Res 26 2 2009 346 355
265. H.A. Patsos, A. Greenhough, D.J. Hicks, M. Al Kharusi, T.J. Collard, and J.D. Lane The endogenous cannabinoid, anandamide, induces COX-2-dependent cell death in apoptosis-resistant colon cancer cells Int J Oncol 37 1 2010 187 193
266. Y.P. Yu, G. Yu, G. Tseng, K. Cieply, J. Nelson, and M. Defrances Glutathione peroxidase 3, deleted or methylated in prostate cancer, suppresses prostate cancer growth and metastasis Cancer Res 67 17 2007 8043 8050
267. B.J. Pettus, C.E. Chalfant, and Y.A. Hannun Ceramide in apoptosis: an overview and current perspectives Biochim Biophys Acta 1585 2-3 2002 114 125
268. M. Mimeault, N. Pommery, N. Wattez, C. Bailly, and J.P. Henichart Anti-proliferative and apoptotic effects of anandamide in human prostatic cancer cell lines: implication of epidermal growth factor receptor down-regulation and ceramide production Prostate 56 1 2003 1 12
269. K. Gustafsson, B. Sander, J. Bielawski, Y.A. Hannun, and J. Flygare Potentiation of cannabinoid-induced cytotoxicity in mantle cell lymphoma through modulation of ceramide metabolism Mol Cancer Res 7 7 2009 1086 1098
270. G. Zolese, T. Bacchetti, A. Ambrosini, M. Wozniak, E. Bertoli, and G. Ferretti Increased plasma concentrations of palmitoylethanolamide, an endogenous fatty acid amide, affect oxidative damage of human low-density lipoproteins: an in vitro study Atherosclerosis 182 1 2005 47 55
271. Y. Chen, and J. Buck Cannabinoids protect cells from oxidative cell death: a receptor-independent mechanism J Pharmacol Exp Ther 293 3 2000 807 812
272. P. Mukhopadhyay, M. Rajesh, H. Pan, V. Patel, B. Mukhopadhyay, and S. Batkai Cannabinoid-2 receptor limits inflammation, oxidative/nitrosative stress, and cell death in nephropathy Free Radic Biol Med 48 3 2010 457 467
273. 1 receptor inhibition leads to decreased vascular AT1 receptor expression, inhibition of oxidative stress and improved endothelial function Basic Res Cardiol 105 4 2010 465 477
274. K.P. Sarker, K.K. Biswas, M. Yamakuchi, K.Y. Lee, T. Hahiguchi, and M. Kracht ASK1-p38 MAPK/JNK signaling cascade mediates anandamide-induced PC12 cell death J Neurochem 85 1 2003 50 61
275. K.K. Biswas, K.P. Sarker, K. Abeyama, K. Kawahara, S. Iino, and Y. Otsubo Membrane cholesterol but not putative receptors mediates anandamide-induced hepatocyte apoptosis Hepatology 38 5 2003 1167 1177
276. S.O. Jacobsson, T. Wallin, and C.J. Fowler Inhibition of rat C6 glioma cell proliferation by endogenous and synthetic cannabinoids. relative involvement of cannabinoid and vanilloid receptors J Pharmacol Exp Ther 299 3 2001 951 959
277. R.S. Samant, and L.A. Shevde Recent advances in anti-angiogenic therapy of cancer Oncotarget 2 3 2011 122 134
278. C. Blazquez, M.L. Casanova, A. Planas, T. Gomez Del Pulgar, C. Villanueva, and M.J. Fernandez-Acenero Inhibition of tumor angiogenesis by cannabinoids FASEB J 17 3 2003 529 531
279. J. Cai, S. Han, R. Qing, D. Liao, B. Law, and M.E. Boulton In pursuit of new anti-angiogenic therapies for cancer treatment Front Biosci 16 2011 803 814
280. G. Thurston Role of angiopoietins and tie receptor tyrosine kinases in angiogenesis and lymphangiogenesis Cell Tissue Res 314 1 2003 61 68
281. J.F. Woessner Jr. Matrix metalloproteinases and their inhibitors in connective tissue remodeling FASEB J 5 8 1991 2145 2154
282. H. Kobayashi, K.C. Boelte, and P.C. Lin Endothelial cell adhesion molecules and cancer progression Curr Med Chem 14 4 2007 377 386
283. A. Preet, R.K. Ganju, and J.E. Groopman Delta9-tetrahydrocannabinol inhibits epithelial growth factor-induced lung cancer cell migration in vitro as well as its growth and metastasis in vivo Oncogene 27 3 2008 339 346
284. M.L. Casanova, C. Blazquez, J. Martinez-Palacio, C. Villanueva, M.J. Fernandez-Acenero, and J.W. Huffman Inhibition of skin tumor growth and angiogenesis in vivo by activation of cannabinoid receptors J Clin Invest 111 1 2003 43 50
285. N.M. Curran, B.D. Griffin, D. O'Toole, K.J. Brady, S.N. Fitzgerald, and P.N. Moynagh The synthetic cannabinoid R(+)WIN 55,212-2 inhibits the interleukin-1 signaling pathway in human astrocytes in a cannabinoid receptor-independent manner J Biol Chem 280 43 2005 35797 35806
286. E.S. Collie-Duguid, and K.W. Wahle Inhibitory effect of fish oil N-3 polyunsaturated fatty acids on the expression of endothelial cell adhesion molecules Biochem Biophys Res Commun 220 1996 969 974
287. S.D. McAllister, R.T. Christian, M.P. Horowitz, A. Garcia, and P.Y. Desprez Cannabidiol as a novel inhibitor of id-1 gene expression in aggressive breast cancer cells Mol Cancer Ther 6 11 2007 2921 2927
288. S.D. McAllister, R. Murase, R.T. Christian, D. Lau, A.J. Zielinski, and J. Allison Pathways mediating the effects of cannabidiol on the reduction of breast cancer cell proliferation, invasion, and metastasis Breast Cancer Res Treat 133 2010 401 404
289. S. Fong, Y. Itahana, T. Sumida, J. Singh, J.P. Coppe, and Y. Liu Id-1 as a molecular target in therapy for breast cancer cell invasion and metastasis Proc Natl Acad Sci U S A 100 23 2003 13543 13548
290. R. Ramer, J. Merkord, H. Rohde, and B. Hinz Cannabidiol inhibits cancer cell invasion via upregulation of tissue inhibitor of matrix metalloproteinases-1 Biochem Pharmacol 79 7 2010 955 966
291. R. Ramer, A. Rohde, J. Merkord, H. Rohde, and B. Hinz Decrease of plasminogen activator inhibitor-1 may contribute to the anti-invasive action of cannabidiol on human lung cancer cells Pharm Res 27 10 2010 2162 2174
292. A. Vaccani, P. Massi, A. Colombo, T. Rubino, and D. Parolaro Cannabidiol inhibits human glioma cell migration through a cannabinoid receptor-independent mechanism Br J Pharmacol 144 8 2005 1032 1036
293. C. Grimaldi, S. Pisanti, C. Laezza, A.M. Malfitano, A. Santoro, and M. Vitale Anandamide inhibits adhesion and migration of breast cancer cells Exp Cell Res 312 4 2006 363 373
294. 1 receptor stimulation on tumor growth and metastatic spreading: actions on signals involved in angiogenesis and metastasis FASEB J 17 12 2003 1771 1773
295. M.P. Endsley, N. Aggarwal, M.A. Isbell, C.E. Wheelock, B.D. Hammock, and J.R. Falck Diverse roles of 2-arachidonoylglycerol in invasion of prostate carcinoma cells: location, hydrolysis and 12-lipoxygenase metabolism Int J Cancer 121 5 2007 984 991
296. L.A. Dailey, and P. Imming 12-Lipoxygenase: classification, possible therapeutic benefits from inhibition, and inhibitors Curr Med Chem 6 5 1999 389 398
297. N. Shukeir, P. Pakneshan, G. Chen, M. Szyf, and S.A. Rabbani Alteration of the methylation status of tumor-promoting genes decreases prostate cancer cell invasiveness and tumorigenesis in vitro and in vivo Cancer Res 66 18 2006 9202 9210
298. R. Franco, O. Schoneveld, A.G. Georgakilas, and M.I. Panayiotidis Oxidative stress, DNA methylation and carcinogenesis Cancer Lett 266 1 2008 6 11
299. L.A. Joss-Moore, Y. Wang, M.L. Baack, J. Yao, A.W. Norris, and X. Yu IUGR decreases PPARgamma and SETD8 expression in neonatal rat lung and these effects are ameliorated by maternal DHA supplementation Early Hum Dev 86 12 2010 785 791
300. D.B. Jump, S.D. Clarke, O. MacDougald, and A. Thelen Polyunsaturated fatty acids inhibit S14 gene transcription in rat liver and cultured hepatocytes Proc Natl Acad Sci U S A 90 18 1993 8454 8458
301. D.B. Jump, S.D. Clarke, A. Thelen, and M. Liimatta Coordinate regulation of glycolytic and lipogenic gene expression by polyunsaturated fatty acids J Lipid Res 35 6 1994 1076 1084
302. D.B. Jump, and S.D. Clarke Regulation of gene expression by dietary fat Annu Rev Nutr 19 1999 63 90
303. K.W. Wahle, D. Rotondo, and S.D. Heys Polyunsaturated fatty acids and gene expression in mammalian systems Proc Nutr Soc 62 2 2003 349 360
304. A.C. Campos, F. Molognoni, F.H. Melo, L.C. Galdieri, C.R. Carneiro, and V. D'Almeida Oxidative stress modulates DNA methylation during melanocyte anchorage blockade associated with malignant transformation Neoplasia 9 12 2007 1111 1121
305. 1 receptor-dependent manner J Biol Chem 283 10 2008 6005 6012
306. M.L. Holland, J.A. Panetta, J.M. Hoskins, M. Bebawy, B.D. Roufogalis, and J.D. Allen The effects of cannabinoids on P-glycoprotein transport and expression in multidrug resistant cells Biochem Pharmacol 71 8 2006 1146 1154
307. S.J. Han, and M. Conti New pathways from PKA to the Cdc2/cyclin B complex in oocytes: Wee1B as a potential PKA substrate Cell Cycle 5 3 2006 227 231
308. 2 cannabinoid receptors as a novel therapy to treat malignant lymphoblastic disease Blood 100 2 2002 627 634
309. 2 receptors PLoS One 5 1 2010 e8688
310. S. Hart, O.M. Fischer, and A. Ullrich Cannabinoids induce cancer cell proliferation via tumor necrosis factor alpha-converting enzyme (TACE/ADAM17)-mediated transactivation of the epidermal growth factor receptor Cancer Res 64 6 2004 1943 1950
311. K. Mnich, D.P. Finn, E. Dowd, and A.M. Gorman Inhibition by anandamide of 6-hydroxydopamine-induced cell death in PC12 cells Int J Cell Biol 2010 2010 818497
312. M. Lee, K.H. Yang, and N.E. Kaminski Effects of putative cannabinoid receptor ligands, anandamide and 2-arachidonyl-glycerol, on immune function in B6C3F1 mouse splenocytes J Pharmacol Exp Ther 275 2 1995 529 536
313. 2 receptors J Neuroimmunol 189 1-2 2007 17 22
314. Lissoni P, Tintori A, Fumagalli L, Brivio F, Messina G, Parolini D, et al. The endocannabinoid anandamide neither impairs in vitro T-cell function nor induces regulatory T-cell generation. Anticancer Res 2008;28(6A):3743-8.
315. L.A. Fouser, J.F. Wright, K. Dunussi-Joannopoulos, and M. Collins Th17 cytokines and their emerging roles in inflammation and autoimmunity Immunol Rev 226 2008 87 102
316. P.C. Calder Fatty acids and immune function: relevance to inflammatory bowel diseases Int Rev Immunol 28 6 2009 506 534
317. C. Galli, and P.C. Calder Effects of fat and fatty acid intake on inflammatory and immune responses: a critical review Ann Nutr Metab 55 1-3 2009 123 139
318. Kundu JK, Surh YJ. Inflammation: gearing the journey to cancer. Mutat Res 2008;659(1-2):15-30.
319. L. De Petrocellis, D. Melck, A. Palmisano, T. Bisogno, C. Laezza, and M. Bifulco The endogenous cannabinoid anandamide inhibits human breast cancer cell proliferation Proc Natl Acad Sci U S A 95 14 1998 8375 8380
320. G.A. Cabral, D.M. Toney, K. Fischer-Stenger, M.P. Harrison, and F. Marciano-Cabral Anandamide inhibits macrophage-mediated killing of tumor necrosis factor-sensitive cells Life Sci 56 23-24 1995 2065 2072
321. M.A. Engel, C.A. Kellermann, T. Rau, G. Burnat, E.G. Hahn, and P.C. Konturek Ulcerative colitis in AKR mice is attenuated by intraperitoneally administered anandamide J Physiol Pharmacol 59 4 2008 673 689
322. Y. Nakajima, Y. Furuichi, K.K. Biswas, T. Hashiguchi, K. Kawahara, and K. Yamaji Endocannabinoid, anandamide in gingival tissue regulates the periodontal inflammation through NF-kappaB pathway inhibition FEBS Lett 580 2 2006 613 619
323. G. D'Argenio, M. Valenti, G. Scaglione, V. Cosenza, I. Sorrentini, and V. Di Marzo Up-regulation of anandamide levels as an endogenous mechanism and a pharmacological strategy to limit colon inflammation FASEB J 20 3 2006 568 570
324. Di Marzo V, De Petrocellis L, Sepe N, Buono A. Biosynthesis of anandamide and related acylethanolamides in mouse J774 macrophages and N18 neuroblastoma cells. Biochem J 1996;316(Pt. 3)(Pt. 3):977-84.
325. V.K. Pestonjamasp, and S.H. Burstein Anandamide synthesis is induced by arachidonate mobilizing agonists in cells of the immune system Biochim Biophys Acta 1394 2-3 1998 249 260
326. R. Sancho, M.A. Calzado, V. Di Marzo, G. Appendino, and E. Munoz Anandamide inhibits nuclear factor-kappaB activation through a cannabinoid receptor-independent pathway Mol Pharmacol 63 2 2003 429 438
327. 2 Mol Pharmacol 73 2 2008 441 450
328. 2 receptor and mediator-dependent stimulation of human whole-blood neutrophils by exogenous and endogenous cannabinoids J Pharmacol Exp Ther 315 2 2005 641 647
329. D.F. Woodward, R.W. Carling, C.L. Cornell, H.G. Fliri, J.L. Martos, and S.N. Pettit The pharmacology and therapeutic relevance of endocannabinoid derived cyclo-oxygenase (COX)-2 products Pharmacol Ther 120 1 2008 71 80
330. M. Glass, J. Hong, T.A. Sato, and M.D. Mitchell Misidentification of prostamides as prostaglandins J Lipid Res 46 7 2005 1364 1368
331. C. Blazquez, L. Gonzalez-Feria, L. Alvarez, A. Haro, M.L. Casanova, and M. Guzman Cannabinoids inhibit the vascular endothelial growth factor pathway in gliomas Cancer Res 64 16 2004 5617 5623
332. T. Gomez Del Pulgar, M.L. De Ceballos, M. Guzman, and G. Velasco Cannabinoids protect astrocytes from ceramide-induced apoptosis through the phosphatidylinositol 3-kinase/protein kinase B pathway J Biol Chem 277 39 2002 36527 36533
333. 2 receptors in the inhibitory effects of cannabinoids on lipopolysaccharide-induced nitric oxide release in astrocyte cultures J Neurosci Res 67 6 2002 829 836
334. H.A. Patsos, D.J. Hicks, R.R. Dobson, A. Greenhough, N. Woodman, and J.D. Lane The endogenous cannabinoid, anandamide, induces cell death in colorectal carcinoma cells: a possible role for cyclooxygenase 2 Gut 54 12 2005 1741 1750
335. A.T. Koki, and J.L. Masferrer Celecoxib: a specific COX-2 inhibitor with anticancer properties Cancer Control 9 2 Suppl. 2002 28 35
336. S. Pisanti, A.M. Malfitano, C. Grimaldi, A. Santoro, P. Gazzerro, and C. Laezza Use of cannabinoid receptor agonists in cancer therapy as palliative and curative agents Best Pract Res Clin Endocrinol Metab 23 1 2009 117 131
337. D. Walsh, K.A. Nelson, and F.A. Mahmoud Established and potential therapeutic applications of cannabinoids in oncology Support Care Cancer 11 3 2003 137 143
338. D. Cota Role of the endocannabinoid system in energy balance regulation and obesity Front Horm Res 36 2008 135 145
339. Nelson K, Walsh D, Deeter P, Sheehan F. A phase II study of delta-9-tetrahydrocannabinol for appetite stimulation in cancer-associated anorexia. J Palliat Care 1994;10(1):14-8.
340. A. Jatoi, H.E. Windschitl, C.L. Loprinzi, J.A. Sloan, S.R. Dakhil, and J.A. Mailliard Dronabinol versus megestrol acetate versus combination therapy for cancer-associated anorexia: a north central cancer treatment group study J Clin Oncol 20 2 2002 567 573
341. Cannabis-In-Cachexia-Study-Group, Strasser F, Luftner D, Possinger K, Ernst G, Ruhstaller T, Meissner W, et al. Comparison of orally administered cannabis extract and delta-9-tetrahydrocannabinol in treating patients with cancer-related anorexia-cachexia syndrome: a multicenter, phase III, randomized, double-blind, placebo-controlled clinical trial from the cannabis-in-cachexia- study-group. J Clin Oncol 2006;24(21):3394-400.
342. S.J. Wigmore, J.A. Ross, J.S. Falconer, C.E. Plester, M.J. Tisdale, and D.C. Carter The effect of polyunsaturated fatty acids on the progress of cachexia in patients with pancreatic cancer Nutrition 12 1 Suppl. 1996 S27 S30
343. K.C. Fearon, M.F. Von Meyenfeldt, A.G. Moses, R. Van Geenen, A. Roy, and D.J. Gouma Effect of a protein and energy dense N-3 fatty acid enriched oral supplement on loss of weight and lean tissue in cancer cachexia: a randomised double blind trial Gut 52 10 2003 1479 1486